ALKERMES | ALKS - 税前利润

金融业

USD

USD 2.49B

现金及等价物

USD 388.57M

USD 46.21M

USD 1.93B

USD 543.44M

USD 71.6M

股息收益率

0

USD -10.95M

USD 100.31M

1.8K

EPS每股收益

USD 0.29

股本和储备

USD 1.82B

USD 338.34M

债务利息支出

USD 12.28M

USD 11.94M

USD 285.82M

USD 5.52B

USD 49.34M

USD 326.44M

USD -10.95M

普通股股本

USD 165.61M

19.54

USD 100.74M

USD 384.5M

销售和管理费用

USD 187.2M

USD 196.63M

贸易债权人

USD 107.95M

应收帐款人

USD 334.03M

	税前利润	更改		日
AbbVie	USD 2.67B		1.71B	2025-12
Acadia Pharmaceuticals	USD 26.32M		18.28M	2025-12
ALKERMES	USD 100.74M		4.1M	2025-09
Amgen	USD 3.92B		2.35B	2025-09
Biogen	USD -56M		613.3M	2025-12
BioMarin Pharmaceutical	USD -26.32M		324.19M	2025-09
Bristol-Myers Squibb	USD 3.11B		1.34B	2025-09
Coherus Biosciences	USD -46.35M		90.86M	2025-12
Eli Lilly	USD 7.23B		456M	2025-09
Gilead Sciences	USD 2.08B		1.56B	2025-12
Heron Therapeutics	USD -2.95M		14.54M	2025-12
Ionis Pharmaceuticals	USD -228M		99M	2025-12
J&J	USD 7.82B		2.86B	2026-03
Merck	USD 6.74B		22M	2025-09
Minerva Neurosciences	USD 22.51M		30.74M	2024-09
Nektar Therapeutics	USD -34.7M		2.35M	2025-12
Neurocrine Biosciences	USD 239.4M		52.4M	2025-12
Otsuka Holdings	JPY 130.23B		54.96B	2026-03
Pfizer	USD 3.33B		290M	2025-09
Regeneron Pharmaceuticals	USD 1.04B		719.6M	2025-12
Vertex Pharmaceuticals	USD 1.3B		15.8M	2025-09